Rapid Diagnostic Test are a type of point-of-care diagnostic, meaning that these assays are intended to provide diagnostic results conveniently and immediately to the patient while still at the health facility, screening site, or other health care provider.

This examination uses a cartridge to see the presence of antibodies in the body when there is a viral or bacterial infection.

BPRO® COVID-19 Ag Rapid Diagnostic Test is an immunochromatographic rapid test for the qualitative detection of specific antigen against the SARS-CoV-2 nucleocapsid protein in nasopharyngeal swab samples.

The clinical performance of the BPRO COVID-19 Ag Rapid Diagnostic Test has been validated by a laboratory appointed by the Indonesian Ministry of Health using 60 nasopharyngeal swab specimens that have been tested for nucleic acid examination (PCR) as many as 30 positive samples with CT≤25 values ​​and 30 negative samples.

  • Sensitivity : 96.67%
  • Specificity : 100.00%
  • Accuracy : 98.33%

More product information